Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ALKERMES RG (NQ: ALKS)
58.47 USD  -0.21 (-0.36%)
Official Closing Price  /  Updated: 8:10 PM EDT, Jun 23, 2017  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 992,352
Open 57.78
Bid (Size) 22.33 (100)
Ask (Size) 64.75 (100)
Prev. Close 58.68
Today's Range 57.56 - 58.79
52wk Range 39.65 - 63.40
Shares Outstanding 145,827,889
Dividend Yield N/A
Performance
YTD
+4.22%
+4.22%
1 Month
+0.91%
+0.91%
3 Month
-1.48%
-1.48%
6 Month
+2.99%
+2.99%
1 Year
+38.29%
+38.29%
Top News
More News
Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive... Read More
from Business Wire News Releases
Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference
Alkermes plc (NASDAQ: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 38th Annual Global Healthcare Conference on... Read More
from Business Wire News Releases
More News
Read More
Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
from Business Wire News Releases
Research Reports Coverage on Drug Delivery Stocks -- Valeant Pharma, Delcath Systems, Alkermes, and Adamis Pharma
from PR Newswire
FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia
from Business Wire News Releases
Alkermes’ Corporate Presentation to Be Webcast at the Jefferies Healthcare Conference
from Business Wire News Releases
Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying
category News , Politics , General , and 17 more.
from Benzinga
Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs
from Business Wire News Releases
Alkermes Has Returned 51.2% Since SmarTrend Recommendation (ALKS)
from Comtex SmarTrend® News Briefs
Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting
from Business Wire News Releases
Alkermes Has Returned 61.6% Since SmarTrend Recommendation (ALKS)
from Comtex SmarTrend® News Briefs
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial